T1	p 133 189	patients with mixed dyslipidaemia and metabolic syndrome
T2	p 393 420	metabolic syndrome ( MetS )
T3	p 601 643	patients with mixed dyslipidaemia and MetS
T4	p 987 1019	patients with MetS were included
T5	i 16 28	rosuvastatin
T6	i 64 75	fenofibrate
T7	i 79 94	?-3 fatty acids
T8	i 468 480	rosuvastatin
T9	i 528 539	fenofibrate
T10	i 543 558	?-3 fatty acids
T11	i 767 779	rosuvastatin
T12	i 826 838	rosuvastatin
T13	i 863 874	fenofibrate
T14	i 911 926	?-3 fatty acids
T15	i 1329 1331	RF
T16	i 1516 1518	RF
T17	i 1704 1705	R
T18	i 1710 1712	R?
T19	o 98 129	lipoprotein subfraction profile
T20	o 566 597	lipoprotein subfraction profile
T21	o 1132 1163	lipoprotein subfraction profile
T22	o 1235 1248	mean LDL size
T23	o 1388 1416	hypotriglyceridemic capacity
T24	o 1469 1487	insulin resistance
T25	o 1540 1552	HDL-C levels
T26	o 1648 1672	of larger HDL subclasses
T27	o 1755 1763	LDL size